Teva Pharmaceutical Industries PE ratio TEVA

Share price divided by earnings per share over the last twelve months, since 2021.

Today, Oct 23, 2026: 65.7×
5-year median: 25.8×
Against its 5-year history: 95th; percentile: 0 is its lowest day, 100 its highest
5-year range: 12.1× to 69.2×
Peer median: 50.1×

Teva Pharmaceutical Industries' PE ratio is 65.7× as of Oct 23, 2026: a share price of $39.41 against $0.60 of earnings per share over the last twelve months.

That is above its 5-year median of 25.8×, higher than on 95% of days in the last 5 years.

Over that time it ranged from 12.1× in Dec 2021 to 69.2× in Oct 2026.

The median for 10 healthcare stocks of a similar size is 50.1×.

PE ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	65.7×	23.2×	69.2×
2025	53.1×	40.0×	53.1×
2024	n/m a value too high to mean anything
2023	n/m a value too high to mean anything
2022	22.9×	12.6×	27.4×
2021	12.1×	12.1×	14.4×

Against its peers

Companies in Healthcare nearest Teva Pharmaceutical Industries' size, closest first, today.

Company	PE ratio
TEVATeva Pharmaceutical Industries	65.7×
IQVIQVIA	34.7×
MDLNMedline	n/m
WATWaters	113×
IDXXIDEXX Laboratories	39.4×
AAgilent Technologies	34.0×
ONCBeOne Medicines	67.6×
HUMHumana	39.9×
EWEdwards Lifesciences	51.2×
ILMNIllumina	50.1×
BDXBecton, Dickinson and	60.1×
Peer median	50.1×

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Teva Pharmaceutical Industries

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.